Post by
Riverfolk on Jul 07, 2022 2:01pm
Globe says Arch seen having "blockbuster potential"
The Globe and Mail reports in its Thursday edition that iA Capital analyst Chelsea Stellick says Arch Biopartners possesses "blockbuster potential to establish a new standard of care" for preventing and treating organ damage with its lead drug candidate Metablok. The Globe's David Leeder writes that Ms. Stellick rates Arch "speculative buy" in new coverage. She set a share target of $6. The Globe notes that Ms. Stellick is the lone analyst covering the stock. Ms. Stellick says in a note: "Because so many diseases or injuries cause inflammation in the lungs, liver, or kidneys, there are many possible permutations for Arch's path to its first product approval. Acute kidney injury (AKI) is the company's lead indication, which affects over six million people annually in the U.S. The optionality of holding a suite of drug candidates applicable to multiple indications will allow Arch to pursue the optimal combination of clinical trials to identify the best niches for DPEP1 inhibition given market size, capital, time, and regulatory considerations. For added diversification via possible future partnerships, developments or monetization opportunities, Arch also holds a small portfolio of unrelated early stage assets."
Comment by
GoldenArm on Sep 09, 2022 2:11pm
So when does ia Capital expect them to hit $6? 2028?